Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Depreciation & Amortization (CF) (2020 - 2025)

Bioventus (BVS) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 5.73% year-over-year to $11.7 million, compared with a TTM value of $47.0 million through Dec 2025, down 5.13%, and an annual FY2025 reading of $47.0 million, down 5.13% over the prior year.
  • Depreciation & Amortization (CF) was $11.7 million for Q4 2025 at Bioventus, up from $11.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $16.9 million in Q4 2022 and bottomed at $7.2 million in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $12.2 million, with a median of $12.3 million recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 73.71% in 2022, then decreased 28.46% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $11.7 million in 2021, then surged by 44.93% to $16.9 million in 2022, then fell by 26.43% to $12.5 million in 2023, then dropped by 0.48% to $12.4 million in 2024, then dropped by 5.73% to $11.7 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BVS at $11.7 million in Q4 2025, $11.4 million in Q3 2025, and $12.0 million in Q2 2025.